Cvrx, Inc. (CVRX) 10-Q Summary: Q2 2026
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Cvrx, Inc. is a commercial-stage medical device company focused on the Barostim neuromodulation system for heart failure (HFrEF) and resistant hypertension. The company operates as a single reportable segment with revenue derived primarily from the U.S. and Europe. As of July 30, 2026, there were 26,641,597 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $15.7 million | $13.6 million | $30.5 million | $25.9 million |
| Gross Profit | $13.7 million | $11.5 million | $26.6 million | $21.8 million |
| Gross Margin | 87% | 84% | 87% | 84% |
| Net Loss | $(14.0) million | $(14.7) million | $(27.2) million | $(28.5) million |
| Diluted EPS | $(0.53) | $(0.57) | $(1.03) | $(1.10) |
| Cash & Equivalents | $64.6 million (as of June 30, 2026) | |||
| Long-Term Debt | $58.6 million (carrying value); $60.0 million principal outstanding | |||
| Operating Cash Flow | $(21.0) million used (YTD 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 16% year-over-year in Q2 and 17% year-over-year for the six months ended June 30, 2026. U.S. revenue grew 21% (Q2) and 21% (YTD), driven by expansion into new sales territories (56 territories vs. 47 in prior year) and increased active implanting centers (258 vs. 240).
- International Decline: European revenue decreased 31% in Q2 and 18% YTD due to lower unit sales (40 units in Q2 2026 vs. 61 in Q2 2025).
- Margin Expansion: Gross margin improved to 87% from 84% in the prior year periods, attributed to higher average selling prices and manufacturing efficiencies.
- Expense Trends: R&D expenses increased 27% (Q2) and 25% (YTD) due to headcount and clinical trial costs. SG&A expenses remained relatively flat in Q2 (+1%) but increased 2% YTD, driven by stock-based compensation and legal fees.
- Debt Financing: In January 2026, the company amended its loan agreement to increase capacity to $100 million and borrowed an additional $10 million, bringing total outstanding principal to $60 million.
Guidance, Outlook, and Risks
- Outlook: Management expects a lower rate of year-over-year revenue growth in the second half of fiscal 2026 compared to the first half. This is attributed to fewer sales territories than anticipated, lower sales force productivity, and prolonged challenges with a major payer.
- Reimbursement: Humana issued a Medicare Advantage coverage policy effective May 1, 2026. CMS proposed retaining the Barostim implant procedure under a specific payment classification with a rate of approximately $45,000, effective January 1, 2027.
- Liquidity: The company believes existing cash resources ($64.6 million) and cash from operations will meet requirements for more than 18 months. An At-The-Market (ATM) offering with Jefferies LLC has $49.2 million remaining capacity.
- Legal Proceedings: On May 14, 2026, the company received a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding potential False Claims Act violations related to marketing practices and kickbacks. The company is cooperating but cannot estimate potential financial loss.
- Risk Factors: Key risks include continued operating losses, dependence on the single Barostim product, reimbursement challenges, and supply chain dependencies.
Investor Verification Checklist
- Verify the status and potential financial impact of the DOJ investigation (CID) received in May 2026.
- Monitor the finalization of the CMS 2027 Outpatient Prospective Payment System rule regarding the $45,000 reimbursement rate.
- Assess the company's ability to meet the performance covenant requiring 50% of the trailing twelve-month revenue target under the amended loan agreement.
- Track the progress of the BENEFIT-HF clinical trial and its impact on expanded patient population indications.
- Review the company's cash burn rate relative to the 18-month liquidity runway provided by management.